An Atraumatic Femoral Fracture in a Patient with Rheumatoid Arthritis and Osteoporosis Treated with Denosumab

Abstract EN

Osteoporosis is responsible for a significant burden both individually and socially, but is readily treated with antiresorptive agents and mineral supplementation.

However, long-term usage of these agents, notably bisphosphonates, is rarely associated with atypical fractures.

Denosumab is a monoclonal antibody that reduces osteoclast activity and thus increases bone mineral density.

In this case report, we present a 78-year-old woman with a background of rheumatoid arthritis and osteoporosis who presented with an atypical diaphyseal femoral fracture.